Diquafosol
From Wikipedia, the free encyclopedia
| Names | |
|---|---|
| IUPAC name
O1,O7-Di(5′-deoxyuridin-5′-yl) tetrahydrogen tetraphosphate
| |
| Systematic IUPAC name
O1,O7-Bis{[(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxyoxolan-2-yl]methyl} tetrahydrogen tetraphosphate | |
| Other names
P1,P4-Bis(5'-uridyl) tetraphosphate; INS-365; Diquafosol tetrasodium
| |
| Identifiers | |
| |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
PubChem CID
|
|
| UNII |
|
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C18H26N4O23P4 | |
| Molar mass | 790.306 g·mol−1 |
| Pharmacology | |
| S01XA33 (WHO ) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Chemical compound
Diquafosol (tradename Diquas) is a pharmaceutical drug for the treatment of dry eye disease. It was approved for use in Japan in 2010.[1] It is formulated as a 3% ophthalmic solution of the tetrasodium salt.
Its mechanism of action involves agonism of the P2Y2 purinogenic receptor.[2]
References
[edit ]- ^ "Santen and Inspire Announce Approval of DIQUAS for Dry Eye Treatment in Japan" (Press release). April 16, 2010.
- ^ Pendergast, W; Yerxa, BR; Douglass Jg, 3rd; Shaver, SR; Dougherty, RW; Redick, CC; Sims, IF; Rideout, JL (2001). "Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates". Bioorganic & Medicinal Chemistry Letters. 11 (2): 157–60. doi:10.1016/S0960-894X(00)00612-0. PMID 11206448.
{{cite journal}}: CS1 maint: numeric names: authors list (link)